Current Clinical Trials

Standard treatment options:

• Supportive care, including growth factor support.[1,2].
• 5-azacitidine.[3]
• Allogeneic stem cell transplantation.[4,5]

Treatment options under clinical evaluation:

• Decitabine.[6]
• Lenalidomide (CC-5013).[7]
• Nonmyeloablative allogeneic stem cell transplantation.

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with secondary myelodysplastic syndromes. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

1. Tricot GJ, Lauer RC, Appelbaum FR, et al.: Management of the myelodysplastic syndromes. Semin Oncol 14 (4): 444-53, 1987.  [PUBMED Abstract]
   
   
2. Boogaerts MA: Progress in the therapy of myelodysplastic syndromes. Blut 58 (6): 265-70, 1989.  [PUBMED Abstract]
   
   
3. Kaminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11 (10): 3604-8, 2005.  [PUBMED Abstract]
   
   
4. Appelbaum FR, Barrall J, Storb R, et al.: Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112 (8): 590-7, 1990.  [PUBMED Abstract]
   
   
5. O'Donnell MR, Nademanee AP, Snyder DS, et al.: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5 (11): 1822-6, 1987.  [PUBMED Abstract]
   
   
6. Issa JP, Garcia-Manero G, Giles FJ, et al.: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (5): 1635-40, 2004.  [PUBMED Abstract]
   
   
7. List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (6): 549-57, 2005.  [PUBMED Abstract]
   
   

Back to Top

< Previous Section  |  Next Section >